Tele-Assessment and Face-to-Face Evaluation of Functional Gait Assessment in Multiple Sclerosis
Launched by ISTANBUL UNIVERSITY - CERRAHPASA · Jun 13, 2021
Trial Information
Current as of May 30, 2025
Unknown status
Keywords
ClinConnect Summary
As with all neurological diseases, it is important to use appropriate outcome measurements in the assessment of balance and gait disorders in patients with Multiple Sclerosis (MS), in order to determine the appropriate program for the patient in physiotherapy and rehabilitation applications, both face-to-face and through telerehabilitation. The scale recommended by a clinical practice guide developed with the support of the American Physiotherapy Association (APTA) and the Academy of Neurological Physiotherapy (ANPT) is the Functional Gait Assessment (FGA). According to this proposal, a Tur...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Having a definite diagnosis of MS of any clinical type according to the 2017 Mc Donalds criteria by a neurologist,
- • 18 years and over
- • Expanded Disability Status Scale (EDSS) score of 2,5-6
- • Not having an attack within the last 30 days
- • Voluntarily giving consent to participate in the study
- • Absence of visual and auditory impairment for completion of assessments
- For Tele-assessment:
- • Having a walking area of at least 3 meters at home to evaluate walking
- • Providing a care provider's supervision to ensure walking safety
- • The patient or the caregiver can use the video conferencing software application from the phone or computer
- Exclusion Criteria:
- • Diagnosis of another neurological disease that affects the level of ambulation other than MS
- • Receiving corticosteroid therapy within the last 1 month
- • Limitation in range of motion of the lower extremities, which may affect standing and walking
- • Pain that negatively affects walking in the lower extremity and lumbar area (etc., coxarthrosis, gonarthrosis, sciatica)
- • Inability to stand up from a sitting position (Timed Up \& Go Test requirement)
About Istanbul University Cerrahpasa
Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, Sisli, Turkey
Patients applied
Trial Officials
Perim Zengin, M.Sc
Principal Investigator
Istanbul University-Cerrahpasa Institute of Postgraduate Education
Burcu Ersöz Hüseyinsinoğlu, Assoc. Prof.
Study Chair
Istanbul University-Cerrahpasa Faculty of Health Science
Burcu Altunrende, Prof. Dr.
Study Chair
Memorial Şişli Hospital, Neurology Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials